Evidence map›Paper›PMID 39499399›Full record

ReviewCardiovascular drugs and therapy2025

AGE-RAGE Axis and Cardiovascular Diseases: Pathophysiologic Mechanisms and Prospects for Clinical Applications.

Bijian Wang, Taidou Jiang, Yaoyu Qi, Sha Luo, Ying Xia, Binyan Lang, Bolan Zhang, Shuzhan Zheng

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cardiovascular drugs and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Bijian WangDepartment of Cardiology, The Affiliated Hospital of Southwest Medical University, No.25, Taiping Street, Luzhou, 646000, Sichuan, China.
Taidou JiangDepartment of Cardiology, The Affiliated Hospital of Southwest Medical University, No.25, Taiping Street, Luzhou, 646000, Sichuan, China.
Yaoyu QiDepartment of Cardiology, The Affiliated Hospital of Southwest Medical University, No.25, Taiping Street, Luzhou, 646000, Sichuan, China.
Sha LuoDepartment of Cardiology, The Affiliated Hospital of Southwest Medical University, No.25, Taiping Street, Luzhou, 646000, Sichuan, China.
Ying XiaDepartment of Cardiology, The Affiliated Hospital of Southwest Medical University, No.25, Taiping Street, Luzhou, 646000, Sichuan, China.
Binyan LangDepartment of Cardiology, The Affiliated Hospital of Southwest Medical University, No.25, Taiping Street, Luzhou, 646000, Sichuan, China.
Bolan ZhangDepartment of Cardiology, The Affiliated Hospital of Southwest Medical University, No.25, Taiping Street, Luzhou, 646000, Sichuan, China.
Shuzhan ZhengDepartment of Cardiology, The Affiliated Hospital of Southwest Medical University, No.25, Taiping Street, Luzhou, 646000, Sichuan, China. toshuzhan@126.com.ORCID 0009-0000-6795-064X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advanced glycation end products (AGE), a diverse array of molecules generated through non-enzymatic glycosylation, in conjunction with the receptor of advanced glycation end products (RAGE), play a crucial role in the pathogenesis of diabetes and its associated complications. Recent studies have revealed that the AGE-RAGE axis potentially accelerated the progression of cardiovascular diseases, including heart failure, atherosclerosis, myocarditis, pulmonary hypertension, hypertension, arrhythmia, and other related conditions. The AGE-RAGE axis is intricately involved in the initiation and progression of cardiovascular diseases, independently of its engagement in diabetes. The mechanisms include oxidative stress, inflammation, alterations in autophagy flux, and mitochondrial dysfunction. Conversely, inhibition of AGE production, disruption of the binding between RAGE and its ligands, or silencing of RAGE expression could effectively impair the function of AGE-RAGE axis, thereby delaying or ameliorating the aforementioned diseases. AGE and the soluble receptor for advanced glycation end products (sRAGE) have the potential to be novel predictors of cardiovascular diseases. In this review, we provide an in-depth overview towards the biosynthetic pathway of AGE and elucidate the pathophysiological implications in various cardiovascular diseases. Furthermore, we delve into the profound role of RAGE in cardiovascular diseases, offering novel insights for further exploration of the AGE-RAGE axis and potential strategies for the prevention and management of cardiovascular disorders.

Indexed as

Cardiovascular DiseasesCardiovascular SystemGlycation End Products, AdvancedReceptor for Advanced Glycation End ProductsAnimalsHumansOxidative StressSignal TransductionGlycation End Products, AdvancedReceptor for Advanced Glycation End ProductsAdvanced glycation end productsCardiovascular diseasesInflammationOxidative stressRAGESRAGE

Identifiers

PMID39499399
PMCPMC12717123

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.